revenu beat reflect strong underli growth across complement
metabol franchis increas guidanc assum on-going growth gmg ultomiri
convers modest contribut nmosd pdufa june optimist
continu rapid convers soliri ultomiri increas investor confid
prospect l-t revenu growth
alexion revenu ep beat consensu alexion rais guidanc
full recap earn see previou note total revenu y/
vs consensu driven double-digit volum growth y/i
partial off-set fx price headwind manag note price
headwind larg due soliri price chang turkey driven soliri formal
reimburs agreement revenu favor impact
addit tender order ex-u market rel product sale growth
deriv y/i asia pacif row
soliri sale q/q y/i vs consensu driven
y/i volum growth favor impact approxim addit
tender order ex-u rel manag note revenu growth
continu driven uptak gmg japan partial off-set
convers pnh patient ultomiri ultomiri sale vs consensu
first full quarter market underli volum growth pnh
ahu includ soliri ultomiri remain solid alexion expect volum
growth high singl digit throughout
strensiq y/i vs revenu consensu
continu underli volum growth y/i strensiq revenu reflect
impact strateg price decis support sustain given weight-bas dose
alexion rais guidanc total revenu previous
soliris/ultomiri revenu previous
non-gaap ep previous metabol sale
non-gaap oper margin unchang guidanc assum continu
growth gmg ultomiri convers modest contribut potenti launch
soliri nmosd june pdufa strong strensiq growth
alexion expect gmg patient constitut largest popul patient
soliri manag also note sever expect headwind
revenu growth includ price fx clinic trial enrol chang row
distribut alexion continu estim price headwind
attribut soliri attribut metabol net hedg alexion expect fx
repres approxim headwind
consist current trend increas soliris/ultomiri estim
total revenu estim non-
gaap ep estim increas dcf-base price target remain
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand
trend soliri remain solid launch gmg set eclips launch pnh
ahu expect fear competit alexion key complement franchis
wain franchis transfer ultomiri follow januari launch strensiq
wit strong launch appear destin blockbust statu
asset plu minor contribut kanuma allow compani post
industry-lead financi view alexion premier orphan diseas compani
expect share appreci investor gain convict alexion abil convert
market ultomiri
 launch soliri nmosd june
european approv ultomiri pnh
initi phase studi ultomiri
soliri sale transfer ultomiri
strensiq kanuma lal-d
achiev
transit franchis
ultomiri rapid assum
soliri ultomiri sale fall short
commerci regulatori setback
strensiq ultomiri
soliri experi meaning
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu next-gen ultomiri
approv pnh approv ahu anticip pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ
ahu market could compar size pnh market soliri also approv
gener myasthenia gavi gmg octob potenti new oppi beyond
soliri strensiq kanuma achiev commerci success
respect peak sale
ultomiri launch pnh track ahead alexion state goal convert
 pnh patient soliri ultomiri april pnh
patient soliri enrol onesourc alexion patient access program
initi treatment ultomiri morn call manag note
bolu convers expect continu steadi rate
commerci live specif coverag polici place addit coverag
decis expect occur payor educ ultomiri cost save
schedul coverag review occur formulari decis made academ
institut thu far ultomiri sale come patient soliri howev
ultomiri may also expand pnh market patient compel initi
therapi due ad conveni six infusions/yr vs soliri
posit chmp opinion ultomiri pnh expect launch prepar
underway germani japan
though werber screen pnh patient phase soliri
biosimilar trial patient yet enrol trial alexion estim earliest
could enter market would approxim three year -- alexion plan
convert major market germani japan ultomiri though
speed ultomiri launch addit european countri outsid germani
impact alexion abil maintain market share pnh territori germani
soliri largest european market alexion aim pnh patient
convert ultomiri
soliri biosimilar approv russia earlier month clinic trial
biosimilar conduct russia data present europ distinct
regulatori requir alexion ip eu give manag confid
impact biosimilar isol russia russian sale soliri constitut
small portion drug overal sale alexion factor financi impact
guidanc
alexion next neurolog indic soliri nmosd patient
estim diagnos nmo popul compel efficaci result
reduct relaps risk phase maintain three year
extens trial patient remain relaps free full data phase trial
present emerg scienc forum present may
soliri sbla nmosd assign june pdufa date launch prepar
underway though fda-approv treatment nmosd rituxan
commonli use off-label reduc relaps risk thu alexion expect soliri
uptak nmosd progress gradual linear fashion initi adopt among
refractori patient today ad soliri nmosd estim model
project nmosd sale
formerli human igg monoclon antibodi develop
waiha gmg result phase i/ii trial waiha previous anticip
howev due issu clinic suppli alexion expect
complet trial addit data releas alexion plan
move phase ii/iii studi waiha gmg year-end earli
morn call manag note issu impur drug product
sourc identifi manufactur issu correct new drug
substanc clinic suppli expect readi use clinic program end
year
phase trial ultomiri gmg underway enrol gmg patient
prior failur immunosuppress therapi broader popul rel soliri
phase trial refractori gmg trial expect enrol patient
clinicaltri gov list primari complet date decemb
new manag done admir job stabil compani grow soliri
sale pnh ahu launch drug gmg indic think favor
financi outlook increas confid compani abil convert patient
ultomiri could posit share re-rat investor gain confid
growth durabl complement franchis alexion one larg
cap biotech solid growth prospect reason likelihood investor
sentiment improv consid top larg cap pick maintain
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi
gmg soliri becom one success ultra-orphan drug
sale y/i pivot trial soliri neuromyel
optica nmo releas posit phase data expect label expans
indic around sbla june pdufa launch follow
next-gener soliri candid ultomiri seek advanc upon
soliriss profil offer greater conveni potenc phase studi
use dose paradigm demonstr non-inferior soliri
trend superior fda approv pnh grant end
decemb alexion plan convert market
ultomiri regulatori file ultomiri ahu submit
april approv anticip subq
formul employ dose on-going initi data
anticip alexion also studi subq co-administ
halozym call could extend dose
interv given steadi new patient add ultomiri abil
protect franchis competit estim sale alexion
complement franchis includ pnh ahu
gmg alexion market two addit ultra-orphan drug strensiq
asfotas alfa hypophosphatasia sever bone diseas approv
 europ japan gener sale
believ drug potenti alexion acquir synageva
bring kanuma enzym replac therapi lal
defici unfortun alexion face challeng identifi lal-d
patient sale like far modest expect model
sale alexion also acquir wilson therapeut april
gain access treatment wilson diseas current phase
develop addit alexion acquir syntimmun
alexion aim move pivot develop
warm autoimmun hemolyt anemia waiha gmg late
view alexion premier orphan diseas compani expect share
appreci investor gain convict durabl alexion
franchis convert market ultomiri
cowen compani
reportedcowen estimatesoliri percent percent percent cowen
full data phase nmosd
anticip approv nmosd
potenti competitor apelli releas result ph trial pnh
anticip launch pnh germani
initi phase ultomiri iv nmosd potenti bridg subq
initi poc studi ultomiri iv al
initi exploratori studi ultomiri iv ppm
data pk-base registr phase bridg studi weekli subq
potenti approv ultomiri ahu
potenti approv ultomiri subq pnh ahu
initi phase ii/iii trial waiha gmg
cowen compani
cowen compani
franchis y/i y/i y/i y/i y/i growthstrensiq sale y/i y/i y/i gross total product oper oper oper incom non- tax net incom y/i base compens incom includ stock includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
franchis sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg compens conting gain loss forward asset liabilitiesaccount expens payable/accru revenuetot use oper invest activitieschang market securitiespay acquisitionspurchas invest financ activitiesdebt issuanc cost excess tax benefit stock option payment mortagag note loan stock salenet proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv singl product soliri risk
expect soliri includ potenti slowdown pnh market unknown
size ahu market regulatori clinic develop risk indic
includ nmo mg alexion share could also wit meaning downsid
meet failur
